19.2% reported weight loss · 3.1% loss with placebo · 52 weeks
15 mg once weekly
Chinese adults with overweight or obesity without diabetes
Full analysis set/total randomized population; intercurrent-event strategy not disclosed. China weight-management NDA acceptance announced June 11, 2026, following positive phase 3 results; no marketing approval verified.
Safety context
15 mg AE discontinuation 0.7%; GI events mainly mild/moderate; no hypoglycemia reported.
Limitations: 19.3% headline is per-protocol; use 19.2% FAS. HKEX filing confirms52-week duration.
2.48 percentage-point HbA1c decrease · 0.28 pp increase with Pooled placebo · 18 weeks
15 mg weekly after six weeks of escalation
Chinese adults aged 18–65 with type 2 diabetes; BMI 19.5–35 kg/m²
ANCOVA with baseline adjustment in participants with evaluable PD data and no major relevant protocol deviations; missing data handled by LOCF.
Safety context
At 15 mg, diarrhea occurred in 9/12 and abdominal distension in 3/12; no hypoglycemia recorded.
Limitations: Small trial. The paper labels the result week 12 of target-dose administration; plotted week18 includes six titration weeks. Pooled placebo combines cohorts with different titration durations.
Status in this atlas: China weight-management NDA acceptance announced June 11, 2026, following positive phase 3 results; no marketing approval verified. Status source
No approved trade name verified. BGM0504 is a development code; the accepted Chinese application does not itself establish marketing approval.
BrightGene Bio-Medical Technology · Originator and developer through its wholly owned Suzhou pharmaceutical subsidiary; planned sole Chinese marketing-authorization holder.; China Resources Sanjiu · Joint development and commercialization partner for the injection in Mainland China.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates both GLP-1 and GIP receptors.
Structure not yet verified
Structure not verified
Activates both GLP-1 and GIP receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.